GSK3β inhibition is involved in the neuroprotective effects of cyclin-dependent kinase inhibitors in neurons

被引:17
|
作者
Vazquez de la Torre, Aurelio [1 ]
Junyent, Felix [1 ,2 ]
Folch, Jaume [2 ]
Pelegri, Carme [3 ]
Vilaplana, Jordi [3 ]
Auladell, Carme [4 ]
Beas-Zarate, Carlos [5 ,6 ]
Pallas, Merce [1 ]
Verdaguer, Ester [4 ]
Carnins, Antoni [1 ]
机构
[1] Nucli Univ Pedralbes, Univ Barcelona, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Unitat Farmacol & Farmacognosia,Fac Farm,Inst Bio, Barcelona 08028, Spain
[2] Univ Rovira & Virgili, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Fac Med & Ciencies Salut, Unitat Bioquim, Reus 43201, Tarragona, Spain
[3] Univ Barcelona, Fac Farm, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Dept Fisiol, E-08028 Barcelona, Spain
[4] Univ Barcelona, Fac Biol, Dept Cellular Biol, Barcelona, Spain
[5] Univ Guadalajara, CUCBA, Dept Biol Celular & Mol, Guadalajara 44340, Jalisco, Mexico
[6] IMSS, CIBO, Div Neurociencias, Guadalajara 44340, Jalisco, Mexico
关键词
Flavopiridol; Roscovitine; GSK3; beta; Cerebellar granular cells; Apoptosis; GLYCOGEN-SYNTHASE KINASE-3; CEREBELLAR GRANULE CELLS; C-JUN; GSK-3; INHIBITORS; CDK INHIBITORS; CANCER-CELLS; ROSCOVITINE; APOPTOSIS; SURVIVAL; PHOSPHORYLATION;
D O I
10.1016/j.phrs.2011.08.006
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the present study, we evaluated the effects of roscovitine (Rosco) and flavopiridol (Flavo), both of which are classified as cyclin-dependent kinase (CDK) inhibitors, on apoptosis induced by the inhibition of PI3K/AKT pathway in cerebellar granule neurons (CGNs). Our results demonstrate that both CDK inhibitors prevented apoptosis induced by LY294002 (LY), as also occurs with SB415286 (SB4), a selective GSK3 beta inhibitor. Our findings also indicate that these CDK inhibitors inhibit GSK3 beta, representing a potential pharmacological mechanism involved in their neuroprotective properties. Thus, the increased activity of GSK3 beta induced by LY294002 and detected by dephosphorylation at Ser9 was prevented by both compounds. Likewise, GSK3 beta activity was measured by a radioactivity assay, revealing that CDK inhibitors and SB415286 prevented the increase in GSK3 beta activity induced by PI3K inhibition. In addition, we analysed c-Jun, which is also a mediator of PI3K inhibition-induced apoptosis. However, neither of the CDK inhibitors nor 513415286 prevented the increase in c-Jun phosphorylation induced by PI3K inhibition. Therefore, our data identify GSK3 beta as a crucial mediator of CGN apoptosis induced by PI3K inhibition and indicate that the antiapoptotic effects of CDKs are mediated by the inhibition of this pharmacological target. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码:66 / 73
页数:8
相关论文
共 50 条
  • [41] Expression of cyclin-dependent kinase inhibitors in vascular disease
    Tanner, FC
    Yang, ZY
    Duckers, E
    Gordon, D
    Nabel, GJ
    Nabel, EG
    CIRCULATION RESEARCH, 1998, 82 (03) : 396 - 403
  • [42] Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer
    Giannone, Gaia
    Tuninetti, Valentina
    Ghisoni, Eleonora
    Genta, Sofia
    Scotto, Giulia
    Mittica, Gloria
    Valabrega, Giorgio
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (09)
  • [43] Cyclin-dependent kinase inhibitors move into Phase III
    Malini Guha
    Nature Reviews Drug Discovery, 2012, 11 : 892 - 894
  • [44] Cyclin-dependent kinase inhibitors closer to market launch?
    Galons, Herve
    Oumata, Nassima
    Gloulou, Olfa
    Meijer, Laurent
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2013, 23 (08) : 945 - 963
  • [45] Functional analysis of cyclin-dependent kinase inhibitors of Arabidopsis
    De Veylder, L
    Beeckman, T
    Beemster, GTS
    Krols, L
    Terras, P
    Landrieu, I
    Van der Schueren, E
    Maes, S
    Naudts, M
    Inzé, D
    PLANT CELL, 2001, 13 (07): : 1653 - 1667
  • [46] ROLE OF THE CYCLIN-DEPENDENT KINASE INHIBITORS IN THE DEVELOPMENT OF CANCER
    HIRAMA, T
    KOEFFLER, HP
    BLOOD, 1995, 86 (03) : 841 - 854
  • [47] Cyclin-dependent kinase inhibitors: novel anticancer agents
    Mani, S
    Wang, CG
    Wu, KM
    Francis, R
    Pestell, R
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (08) : 1849 - 1870
  • [48] Cyclin-dependent kinase 7 inhibitors in cancer therapy
    Wang, Minmin
    Wang, Tianyu
    Zhang, Xiangyu
    Wu, Xiaoxing
    Jiang, Sheng
    FUTURE MEDICINAL CHEMISTRY, 2020, 12 (09) : 813 - 833
  • [49] Cyclin-dependent kinase inhibitors move into Phase III
    Guha, Malini
    NATURE REVIEWS DRUG DISCOVERY, 2012, 11 (12) : 892 - 894
  • [50] Cyclin-dependent kinase inhibitors (CKIs) and hematological malignancies
    Baghdassarian, N
    Ffrench, M
    HEMATOLOGY AND CELL THERAPY, 1996, 38 (04): : 313 - 323